Key result
Direct thrombin inhibitors were as efficacious as warfarin for preventing vascular death and ischaemic events (OR 0.94; 95% CI 0.85-1.05), and were associated with fewer major haemorrhagic events.
Why the study?
Do direct thrombin inhibitors reduce vascular deaths and ischaemic events compared to vitamin K antagonists in people with non-valvular atrial fibrillation?
Meta-Analysis (n=27,557)
Do direct thrombin inhibitors reduce vascular deaths and ischaemic events compared to vitamin K antagonists in people with non-valvular atrial fibrillation?
Odds Ratio: 0.94 (95% CI 0.85–1.05)
Direct thrombin inhibitors are as efficacious as warfarin for preventing vascular death and ischaemic events in non-valvular AF, with fewer major haemorrhagic events but higher rates of treatment discontinuation.
No takes yet. Share an insight, caveat, or question.
Dabigatran 150 mg twice daily may reduce ischaemic events and major bleeding versus warfarin; extends RCT evidence supporting DTIs in non-valvular AF.
Salazar et al. (2014) conducted a meta-analysis in Non-valvular atrial fibrillation (n=27,557). Direct thrombin inhibitors vs. Vitamin K antagonists (warfarin) was evaluated on Vascular death and ischaemic events (OR 0.94, 95% CI 0.85 to 1.05). Direct thrombin inhibitors were as efficacious as warfarin for preventing vascular death and ischaemic events (OR 0.94; 95% CI 0.85-1.05), and were associated with fewer major haemorrhagic events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: